SomaGenics is developing novel RNA-based treatments for significant unmet medical needs. The Company’s proprietary sshRNA® RNAi effector technology is at the heart of its therapeutic programs. SomaGenics has a proven track record of original research and publication as well as applied development and commercialization. Founded by Brian Johnston, Ph.D., an internationally recognized researcher in the field of nucleic acids, SomaGenics has raised over $28 million, primarily from SBIR grants, and established an impressive intellectual property portfolio covering its nucleic acid-based technologies for life science research, therapeutics and diagnostics. With the advancement of our therapeutic programs, we are seeking private funding to fund late-stage preclinical and clinical development through both investment and strategic partnerships. SomaGenics is engaged in two therapeutic programs: hepatitis delta virus and diabetic wound healing. It has a research-intensive staff trained at institutions including UC Berkeley, Yale, MIT, and UCSF. In the pursuit of our therapeutic goals, SomaGenics’ scientists have also invented a series of technologies for improved detection of RNA, in the form of kits for making more faithful libraries for RNA-seq as well as superior RT-qPCR kits. This business, which has experienced rapidly increasing revenues from sales of kits and services to the research market, was spun out into a new company, RealSeq Biosciences, in 2019, allowing SomaGenics focus on its pharmaceutical business goals. The Company’s commercialization strategy is to enter into development partnerships or license agreements with companies that have complementary technologies as as with companies with an established market presence.